Single Nucleotide Polymorphism (SNP) Genotyping Market Report 2026

The single nucleotide polymorphism (snp) genotyping market size has grown rapidly in recent years. It will grow from $12.34 billion in 2025 to $14.69 billion in 2026 at a compound annual growth rate (CAGR) of 19.1%. The growth in the historic period can be attributed to limited early-stage genotyping capabilities, growing demand in research, high cost of genomic analysis, rising collaboration between research labs, early adoption in pharmacogenomics.

The single nucleotide polymorphism (snp) genotyping market size is expected to see rapid growth in the next few years. It will grow to $29.74 billion in 2030 at a compound annual growth rate (CAGR) of 19.3%. The growth in the forecast period can be attributed to development of high-throughput SNP platforms, increasing adoption in personalized medicine, integration with AI for predictive analysis, expansion into clinical diagnostics, growth in agricultural genomics applications. Major trends in the forecast period include integration with pharmacogenomics, growth in disease risk prediction, increasing use in agriculture and animal breeding, adoption of microarray-based genotyping, rise in point-of-care SNP testing.

The growing burden of chronic conditions is expected to drive the expansion of the single nucleotide polymorphism (SNP) genotyping market in the coming years. Chronic conditions are health issues that persist for a year or more and often require ongoing medical care, limit daily activities, or both. SNP genotyping plays a critical role in identifying genetic predispositions and supporting personalized medicine, particularly as the prevalence of chronic diseases continues to rise. For example, in April 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal agency, reported that in 2023, around 194 million U.S. adults, or 76.4%, had at least one chronic condition. The prevalence was reported at 59.5% among young adults, 78.4% among midlife adults, and 93% among older adults. Therefore, the increasing burden of chronic conditions is fueling the growth of the single nucleotide polymorphism (SNP) genotyping systems market.

Major companies operating in the single nucleotide polymorphism (SNP) genotyping market are focusing on developing biomarkers that aid in the detection of coronary heart disease to strengthen their market position. SNP biomarkers linked to coronary heart disease (CHD) detection are specific genetic variations identified through genomic research that are associated with an elevated risk or susceptibility to CHD. For instance, in February 2023, Cardio Diagnostics, a US-based biotechnology company, launched PrecisionCHD, an AI-driven blood test that integrates epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers for CHD detection. The test uses a machine-learning model to deliver over 75% sensitivity for both men and women and offers a non-invasive solution suitable for in-office or at-home blood sample collection. By relying solely on biomarker data rather than self-reported information, the test removes the need for conventional diagnostic methods such as stress tests and ensures greater objectivity.

In December 2023, Neogen Corporation, a US-based food safety company specializing in genomic technologies, including single nucleotide polymorphism (SNP) genotyping, partnered with TerraNova Equestrian Center. This partnership is intended to strengthen biosecurity measures at TerraNova Equestrian Center through the use of Neogen’s advanced cleaning and disinfectant solutions. The collaboration focuses on protecting the health of horses and their owners while supporting a safe environment for equestrian events and competitions. TerraNova Equestrian Center is a US-based organization that provides a premier facility for riders and horses.

Major companies operating in the single nucleotide polymorphism (snp) genotyping market are Thermo Fischer Scientific Inc, Danaher Corporation, Roche Diagnostics Corporation, GE HealthCare Technologies Inc, Eurofins Genomics LLC, Beckman Coulter Inc, Bio-Rad Laboratories Inc, Qiagen N.V, Sigma-Aldrich Corporation, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Promega Corporation, GenScript Biotech Corporation, Integrated DNA Technologies Inc, LGC Ltd, Sequenom Inc, Fluidigm Corporation, Oxford Gene Technology, Affymetrix Inc, PREMIER Biosoft International Inc, Rubicon Genomics, Xcelris Genomics, Douglas Scientific LLC, Golden Helix Inc.

North America was the largest region in the single nucleotide polymorphism (SNP) genotyping market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single nucleotide polymorphism (snp) genotyping market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single nucleotide polymorphism (snp) genotyping market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the single nucleotide polymorphism genotyping market by raising prices for imported reagents, microarrays, PCR machines, and sequencing instruments. Research laboratories, pharmaceutical companies, and agricultural biotechnology users in Asia-Pacific and Europe are particularly impacted due to dependence on global suppliers. These higher costs can delay large-scale genotyping and pharmacogenomics projects. At the same time, tariffs are driving local production of genotyping kits and analytical platforms, supporting long-term supply resilience in the SNP genotyping market.

The single nucleotide polymorphism (snp) genotyping market research report is one of a series of new reports that provides single nucleotide polymorphism (snp) genotyping market statistics, including single nucleotide polymorphism (snp) genotyping industry global market size, regional shares, competitors with a single nucleotide polymorphism (snp) genotyping market share, detailed single nucleotide polymorphism (snp) genotyping market segments, market trends and opportunities, and any further data you may need to thrive in the single nucleotide polymorphism (snp) genotyping industry. This single nucleotide polymorphism (snp) genotyping market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Single nucleotide polymorphism (SNP) genotyping is a process used to identify and characterize genetic variations at the level of individual DNA nucleotides. It detects specific SNPs, which are single-base changes in DNA sequences, and plays a key role in understanding genetic variation associated with diseases, traits, and population studies.

The main products in single nucleotide polymorphism (SNP) genotyping include consumables, instruments, and services. Consumables are items that are used up during routine operations and require regular replacement, such as laboratory reagents and supplies. The technologies involved include TaqMan SNP genotyping, mass array SNP genotyping, SNP gene chip arrays, and others, and are applied across areas such as animal genetics, plant improvement, diagnostic research, pharmaceuticals and pharmacogenomics, agricultural biotechnology, and additional applications.

The single nucleotide polymorphism (SNP) genotyping market includes revenues earned by providing sample collection, DNA extraction, high-resolution melting analysis, and related next-generation sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. The single nucleotide polymorphism (SNP) genotyping market consists of sales of mass spectrometry-based SNP genotyping and allele-specific PCR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.